Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 14/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20357942 | 0.95 | SYK (0.33) | PDPK1SYKAAK1SSTR4NR1H4 | |
| SCHEMBL18300147 | 0.89 | PDPK1 (0.35) | PDPK1SYKAAK1SSTR4GRM4 | |
| SCHEMBL18300527 | 0.88 | PDPK1 (0.35) | PDPK1SYKAAK1SSTR4GRM4 | |
| SCHEMBL18300427 | 0.84 | SYK (0.36) | PDPK1SYKAAK1SSTR4NR1H4 | |
| SCHEMBL3738636 | 0.81 | SSTR4 (0.37) | PDPK1SYKAAK1SSTR4NR1H4 | |
| SCHEMBL17981437 | 0.80 | PDPK1 (0.35) | PDPK1AAK1SSTR4 | |
| SCHEMBL960748 | 0.80 | SSTR4 (0.37) | PDPK1SYKAAK1SSTR4 | |
| SCHEMBL18300649 | 0.78 | PDPK1 (0.37) | PDPK1SYKAAK1SSTR4NR1H4 | |
| SCHEMBL18300644 | 0.77 | SSTR4 (0.34) | PDPK1SYKAAK1SSTR4 | |
| SCHEMBL833581 | 0.76 | PDPK1 (0.32) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9815853-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2016201052-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | KLKB1, KLK1, KLK2 | PDPK1 688/4885SYK 3998/4885AAK1 1069/4885 |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | PDPK1 688/4885SYK 3998/4885AAK1 1069/4885 |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | PDPK1 688/4885SYK 3998/4885AAK1 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.